Avantor, Inc.

Avantor, Inc.(AVTR)股票分析

$16.420

+0.337 (+2.05%)收盘时

Loading chart…
最高
16.450
开盘
16.100
成交量加权均价
16.27
成交量
29.36M
市值
14.55B
最低
15.950
成交额
477.73M
企业价值/息税折旧摊销前利润(TTM)
15.84

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company's segments include Bioscience & Medtech Products and VWR Distribution & Services. Through these segments, it provides materials and consumables, equipment and instrumentation and services and specialty procurement to customers in biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and others.

AI 分析 of Avantor, Inc. (AVTR)

买入

Avantor Inc is a good buy right now due to its current price of $16.42, which is below the analyst price targets of $15 to $17, suggesting upside potential. The stock has shown a strong year-to-date change of +43.28%, indicating positive momentum. However, the company has faced challenges with a negative net income in Q3 2025, which is a risk to consider.

估值指标

Avantor, Inc.(AVTR)当前预期市盈率为 16.86,5 年平均预期市盈率为 18.34。

预期市盈率

合理
5 年均值 P/E
18.34
当前P/E
16.86
高估
23.27
低估
13.41

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
17.57
当前EV/EBITDA
15.84
高估
31.24
低估
3.89

预期市销率

合理
5 年均值 P/S
1.94
当前P/S
1.61
高估
2.53
低估
1.35

Alphio AI 对 AVTR 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AVTR

$16.34

情景价格

基

基准

基准 · 50%AVTR

$14.73

情景价格

悲

悲观

悲观 · 25%AVTR

$12.25

情景价格

持有 AVTR 的大户

Y

Yacktman Asset Management LP

+ 持有AVTR

+7.03%

3个月收益率

G

Greenhaven Associates Inc

+ 持有AVTR

+3.20%

3个月收益率

F

First Pacific Advisors, LP

+ 持有AVTR

+0.94%

3个月收益率

A

Arlington Value Capital, LLC

+ 持有AVTR

+0.31%

3个月收益率

S

Southeastern Asset Management, Inc.

+ 持有AVTR

-1.97%

3个月收益率

N

NewSouth Capital Management, Inc.

+ 持有AVTR

-3.24%

3个月收益率

事件时间线

2026-09-21 (ET)

06:30:00

Avantor Appoints Todd Garner as EVP and CFO

2026-07-29 (ET)

17:00:00

Federal Reserve Holds Rates Steady, Major Indices Drop Significantly

12:30:00

Dow Jones Drops 874.35 Points as Oil Prices Surge

06:30:00

Raises FY26 Organic Revenue View to Down 0.5% to Up 0.5%

06:30:00

Company Reports Q2 Revenue of $1.69B, Exceeding Expectations

资讯

AVTR 常见问题 —— 由 Alphio AI 解答

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company's segments include Bioscience & Medtech Products and VWR Distribution & Services. Through these segments, it provides materials and consumables, equipment and instrumentation and services and specialty procurement to customers in biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Avantor Inc is a good buy right now due to its current price of $16.42, which is below the analyst price targets of $15 to $17, suggesting upside potential. The stock has shown a strong year-to-date change of +43.28%, indicating positive momentum. However, the company has faced challenges with a negative net income in Q3 2025, which is a risk to consider.

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易